Dr Michel Vaillant
Dr Michel Vaillant has a background in Biology, Statistics and Epidemiology from the Universities of Montpellier and Bordeaux, France.
He has applied up-to-date statistical methods to different clinical and epidemiological studies from analysis of variance to linear mixed models or generalized mixed models in the field of neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
He has developed collaborations with partners acting in Poverty Related Infectious Diseases. With a strong background in Malaria epidemiology and clinical trials, Michel has been project leader for the data management and statistics aspects of 3 large clinical trials (≈ 3400 patients) with WHO/TDR.
Michel teaches data management at the University of Metz and participates in the WHO/TDR capacity building programme, which allows African visiting scientists to be trained.
- MEMOLINGUA, an LIH-funded neuroimaging project with the objective to observe the functional areas of the brain that are linked to the cognitive reserve and protection against the occurrence of Cognitive Impairment. (Biostatistician) 2015-2018
- GATIFLOXACIN: Establishment of a database for a phase 3 clinical trial of tuberculosis (gatifloxacin-containing 4-month regimen vs. standard 6-month TB regimen) in SouthAfrica, Kenya, Guinea, Senegal and Benin– 15,000 $ (validation of procedures for transfer of database) + 195,000 $, 2011-2015
- MOXIDECTIN: Establishment of a database for a phase 3 clinical trial of onchocerciasis (moxidectin vs. standard ivermectin), Statistical Analysis and reporting in Liberia, Democratic Republic of Congo and Ghana – 128,800 $, 2012-2016
- Project co-funded by the LIH, an anonymous donor and the National Research Fund Luxembourg (FNR) in the framework of the PROVIE program. Can non motor signs be premotor signs in Parkinson’s disease? A longitudinal multicenter case-control study. (Biostatistician) 2005-2010
- National Research Fund Luxembourg (FNR) in the framework of the BIOSAN program. MEMOVIE, a project with the objective to examine in a prospective way, the biological factors (including genetic traits) and medical conditions associated with the occurrence and evolution of Moderate Cognitive Impairment (MCI) to Alzheimer-like Disease (AD). (Biostatistician) 2003-2012